查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854163

HIV临床试验市场按药物类别、试验阶段、最终用户、给药途径、分销管道和患者年龄组划分－2025-2032年全球预测

HIV Clinical Trials Market by Drug Class, Trial Phase, End User, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，爱滋病临床试验市场规模将达到 21.9 亿美元，复合年增长率为 7.43%。

关键市场统计数据
基准年2024年 12.3亿美元
预计年份：2025年 13.3亿美元
预测年份 2032 21.9亿美元
复合年增长率 (%) 7.43%

本文简要概述了现代爱滋病临床试验现状，重点介绍了创新驱动因素、营运限制以及相关人员的策略要务。

全球开发安全、有效且可及的爱滋病疗法的努力已进入一个创新加速和务实调整的时期。抗病毒机制的科学进步、试验设计的改进以及对以患者为中心的疗效指标日益增长的关注，都与人们对运营效率和公平获取的日益增长的期望相辅相成。同时，临床试验赞助者、临床实验和研究中心都面临着不断变化的监管要求和复杂的临床实验链，这需要他们做出相应的调整规划。

本执行摘要旨在帮助决策者深入了解影响现代爱滋病临床试验的关键因素。它明确了核心的科学和营运驱动因素，重点指出了可能扰乱研发进度的系统性风险，并为相关人员提供了增强专案韧性的实用方法。摘要整合了临床、后勤和政策观点，为领导者提供了清晰的观点，以便他们在确保伦理和监管严谨性的同时，优先考虑投资、改善伙伴关係并加速转化研究进程。

应将资源分配到哪些方面以改善研究人员的招募和留任？应如何预见和管理跨境营运摩擦？哪些共同研究模式最有可能在不损害安全性和资料完整性的前提下，缩短获得可靠证据的时间？

科学突破、监管现代化和数位转型如何重新定义爱滋病临床试验模式和营运重点

科学突破、数位转型和政策演变正在重塑爱滋病临床试验。分子病毒学和新型药物的进步正在拓展治疗途径，而适应性试验设计和分散式管理模式也开始改变受试者的招募、监测和留存方式。这些转变正在减少传统的瓶颈，并创造机会更有效率地检验更具针对性的假设。同时，数位化终点、远端监测平台和电子源资料撷取的应用，使得以患者为中心的持续性评估成为可能，并减轻了研究中心的负担。

全球监管机构也展现出对创新方法的开放态度，尤其是在试验设计中明确考虑风险缓解措施并实施严格的资料品管时。然而，这种监管开放性也带来了对资料来源、设备检验和受试者保护的更高期望，因此需要儘早进行对话与合作。此外，官民合作关係和产学研联盟的兴起正在加速转化研究，但也引发了关于资料共用、智慧财产权管理和利益公平分配等重要议题。

随着这些变革力量的汇聚，相关人员必须平衡速度与严谨性、创新与可近性。务实地整合新技术，并辅以深思熟虑的相关人员参与和增强供应链韧性，将决定哪些专案能够充分发挥其潜力，带来意义深远的临床进展。

评估美国关税及相关贸易政策转变如何重塑爱滋病临床试验供应链、营运成本和国际合作动态。

近期美国关税及相关贸易政策的调整对爱滋病临床试验生态系统产生了显着的间接影响，主要体现在上游成本和物流格局的改变，而非直接改变科学典范。原料药、专用实验室设备和关键包装组件的关税可能延长采购前置作业时间，并推临床实验药物生产和临床供应链中的常规采购成本。因此，临床试验赞助者和製造外包生产商越来越重视双重采购、库存缓衝以及与报关行密切协调，以确保临床实验按时进行。

除了材料成本之外，关税还会使支撑全球临床试验网络的跨国合作变得复杂。依赖进口诊断剂和低温运输的研究机构可能会面临意想不到的短缺和海关延误，如果不能积极应对，可能会扰乱检体处理并损害资料完整性。此外，关税带来的成本压力可能会加剧辅助服务的价格谈判，导致一些申办者重新评估实验室服务的地理分布、中心实验室整合或更多地依赖区域供应商。

重要的是，关税的影响与政策和营运应对措施密切相关，例如监管灵活性（用于检验替代供应商）、加快临床用品进口授权，以及在申办者和供应商之间分配风险的合约条款。展望未来，产业领导者应预见关税波动将继续影响供应计划，并应纳入基于情境的风险评估、加强供应商管治以及提高端到端物流可视性，以保护临床项目免受不必要的干扰。

从细分市场的观点主导，探讨治疗层级、临床试验阶段、治疗环境、给药途径、通路和患者年龄等因素如何相互作用，进而影响临床试验的策略选择。

細項分析揭示了不同治疗类别、临床试验阶段、治疗环境、给药途径、通路和患者族群的差异化策略意义。按药物类别分类决定了治疗研发的不同优先事项：整合酶链转移抑制剂，例如比克替拉韦、多替拉韦、埃尔维特格拉韦和拉替拉韦，有助于简化治疗方案，但需要关注药物交互作用和抗药性监测。非核苷类逆转录酶抑制剂，例如依非韦伦、依曲韦林、奈韦拉平和利匹韦林，其安全性和中枢神经系统耐受性特征需纳入试验设计；而核苷类逆转录酶抑制剂，例如恩曲他滨、拉米夫定、替诺福韦和齐多夫定，仍是骨干策略的核心。蛋白酶抑制剂，例如阿扎那韦、达芦那韦、福沙那韦和洛匹那韦，需要评估其代谢和依从性，这些因素会影响终点的选择。

根据试验阶段的不同，重点也会有所变化：I期和IIa/IIb期侧重于安全性和概念验证，III期侧重于更广泛的疗效和比较终点，而IV期则侧重于真实世界安全性。临床试验的阶段会影响样本大小、操作复杂性和监测强度，进而影响研究中心的照护现场临床实验和全面监测，而研究机构，包括学术中心和合约研究组织，通常提供专业知识和密集的数据监测。

给药途径（注射、口服、经皮）的选择会影响病患的接受度和供应链要求。注射剂需要低温运输和无菌配製能力，而口服方案则更着重于提高患者的依从性。分销通路（医院、线上和零售药局，零售药局又分为连锁店和独立药局）的差异会影响配药流程和临床实验后药物取得计画。最后，患者族群（成人、老年人、儿童）的差异也需要对安全性监测、知情同意流程和终点选择进行调整，以确保临床试验能够针对不同族群产生具有临床意义的证据。

深入了解美洲、欧洲、中东和非洲以及亚太地区的区域营运和监管情况，为临床实验选址和执行策略提供基础。

区域动态对研究设计、营运执行和监管参与有显着影响。儘管美洲地区完善的研究基础设施和成熟的法律规范使许多申办方能够迅速启动试验，但该地区内部的地域差异也要求对试验中心进行仔细评估，以确保受试者俱有代表性并享有公平的试验机会。北美临床试验中心通常引领临床实验创新，而拉丁美洲临床试验中心则在验证真实世界疗效和扩大受试者多样性方面发挥关键作用。

欧洲、中东和非洲的监管环境各不相同，既有协调统一的努力，也有各地区特有的要求。在这一广袤地区开展业务的申办方必须权衡经验丰富的学术中心和庞大的患者群带来的优势，以及伦理审查时间长短不一和行政流程繁琐等问题。在许多司法管辖区，投资于能力建构、标准化资料撷取流程以及早期与监管机构对话已被证明对减少延误和维持资料品质至关重要。

亚太地区拥有快速成长的临床研究能力，并具备多样化的报销和监管途径。该地区为加快患者招募和接触多元化患者群体提供了机会，但成功与否取决于文化适应性强的招募策略、当地研究者的积极参与以及完善的供应链计划，以应对进口和临床实验交付等问题。在所有地区，临床实验临床实验架构与当地临床实验实践相契合、当地相关人员的积极参与以及对研究中心培训和品质监管的投入，对于获得完整且可推广的证据至关重要。

提供有关主要赞助商、合作模式和服务供应商的信息，这些因素共同塑造了爱滋病毒临床开发领域的营运绩效和转化动力。

参与 HIV 临床开发的公司的竞争格局包括成熟的製药赞助商、专业的生技药品开发商、合约研究和委外研发机构、学术联盟以及专注于数据、物流和病人参与的服务供应商，而新兴企业和生物技术创新者则提供专注于差异化作用机制和目标人群的利基提案主张。

从产业界与学术中心之间的策略联盟到共用方案和数据的多方相关人员，共同研究模式正日益凸显，成为分散风险和加速证据生成的重要途径。委外研发机构和专业服务供应商在营运复杂的测试环节中发挥关键作用，例如长效注射剂的生产、低温运输管理和分散式测试环节。提供电子资料收集、远端监控和可互通实验室资讯系统等技术供应商对于确保资料完整性和合规性也日益重要。

在这个生态系统中，领导力取决于科学清晰度和卓越营运的整合。那些能够将精准的机制假设与强有力的研究中心管治、灵活的供应安排以及符合当地实际情况的招募策略相结合的机构，将更有能力开展高品质的临床试验，并获得具有临床意义的结果。

为赞助商和营运领导者提供可操作的建议，以增强 HIV 临床试验中的供应弹性、监管协调、参与者参与和共同研究模式。

产业领导者应优先采取一系列切实可行的措施，以增强韧性、加快证据产生并确保公平取得。首先，投资多元化的供应商网路和合约机制，以维持临床实验药物和关键检测试剂的持续供应。其次，精心整合分散式试验要素，以减轻受试者负担，同时保持严格的监控控制和有效的远端资料收集。

第三，儘早并经常与监管机构和伦理委员会沟通，以就适应性设计、生物标记终点和安全监测框架达成一致。第四，制定符合当地实际情况且兼顾文化敏感性的招募和保留策略，尤其是在涉及多个地区和人群的临床试验中。第五，实施资料管治，以确保互通性、可追溯性和快速审核，从而满足监管要求和已发布的标准。

最后，促进合作联盟和官民合作关係，共用非竞争性数据和基础设施，将降低小型开发人员的进入门槛，并加速比较效果研究。透过将这些措施纳入专案规划，领导者可以降低营运风险，优化资源分配，并提高试验产生具有临床实用性和普遍适用性结果的机率。

一种透明的三角调查方法，整合了访谈、文献研究、营运案例研究和严​​格的检验，以确保测试资讯的可靠性。

本报告的分析是基于三角测量调查方法，该方法结合了对关键意见领袖的访谈、对同行评审文献和官方监管文件的二手研究，以及对近期爱滋病临床试验计画的案例研究。主要资讯来源包括对首席研究员、临床实验营运负责人、供应链管理人员和患者咨询负责人的结构化访谈，以了解第一线挑战和新兴最佳实践。二手资讯来源包括临床实验试验报告、监管指导文件和方法学文献，这些资料为研究设计、安全性监测和终点选择提供了基础。

所采用的分析框架包括风险映射（用于识别供应链脆弱性）、决策树模型（用于选址）以及相关人员影响矩阵（用于确定缓解策略的优先顺序）。检验步骤包括将访谈内容与已记录的测试结果最后覆核，以及由外部专家进行迭代审查，以确保解释的准确性。品管包括查找所有引用的监管意见，以及保留访谈记录和综合笔记的内部审核追踪。

报告发布后，贸易政策和监管指导方针可能会发生变化。为减少这些局限性，本调查方法强调透明的假设、基于情境的分析，以及对实际观察到的情况与专家预测的明确区分。

一项策略综合，整合了营运要务、协作方法和以参与者为中心的设计，以指导有效的 HIV 临床开发决策。

整合观点、营运和观点，观点参与爱滋病临床研发的机构提供一套连贯的优先事项。目前最迫切的挑战是如何将创新的临床试验设计与务实的执行结合。应利用适应性和分散性要素来提高效率，同时确保有效的资料流和符合法规要求。同样重要的是，鑑于供应检体韧性和供应商管治对招募延迟和样本处理品质的影响，必须将其视为试验可行性不可或缺的一部分，而非事后考虑的因素。

从策略层面来看，申办方应寻求整合产业界、学术界和专业服务供应商优势的合作架构，以加速转化研究进程并扩大受试者群体的多样性。营运负责人必须投资于支援远端监测、标准化实验室操作和文化适应性招募的数位化和人力资源基础设施。最后，与监管机构和社区相关人员保持持续沟通将有助于开发新的终点指标，并增强公众对试验结果的信心。

将科学抱负与营运严谨性相结合、预测并减轻供应和政策风险、并将参与者需求纳入试验设计的组织，将更有能力提供强有力的、可操作的证据，从而推进爱滋病毒感染者的治疗和获得治疗的机会。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将长效注射抗逆转录病毒疗法纳入常规爱滋病治疗，以提高药物依从性
  • 针对多种 HIV-1 谱系的广谱中和抗体检测技术取得进展，以提高其疗效
  • 引入一种利用远端医疗的去中心化临床试验模式，以提高爱滋病研究中病患的留存率
  • 开发一种双效治疗性疫苗，旨在增强爱滋病患者的免疫力并减少病毒库大小。
  • 探索基于 CRISPR 的基因编辑方法作为早期 HIV 临床试验中潜在的功能性治癒手段
  • 运用真实世界数据分析来开发适应性试验设计并优化爱滋病药物开发平臺

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依药物类别分類的爱滋病临床试验市场

  • 进入抑制剂
    • 恩夫韦地
    • 马拉威罗克
  • 整合酶链转移抑制剂
    • 比克替拉韦
    • 多替拉韦
    • 埃尔维特格拉维尔
    • 雷替拉韦
  • 非核苷类逆转录酶抑制剂
    • 依法韦仑
    • 依曲韦林
    • 奈韦拉平
    • 利匹韦林
  • 核苷类逆转录酶抑制剂
    • 恩曲他滨
    • 拉米夫定
    • 替诺福韦
    • 齐多夫定
  • 蛋白酶抑制剂
    • 阿扎那韦
    • 达芦那韦
    • 福沙那韦
    • 洛匹那韦

9. 按试验阶段分類的爱滋病临床试验市场

  • 第一阶段
  • 第二阶段
    • 第二阶段a
    • IIb期
  • 第三阶段
  • 第四阶段

第十章：以最终用户分類的爱滋病临床试验市场

  • 诊所
  • 医院
  • 研究机构
    • 学术机构
    • 合约研究组织

第十一章：按给药途径分類的爱滋病临床试验市场

  • 注射
  • 口服
  • 经皮

12. HIV临床试验市场按分销管道划分

  • 医院药房
  • 网路药房
  • 零售药局
    • 连锁药局
    • 独立药房

13. 按病患年龄组别分類的 HIV 临床试验市场

  • 成人
  • 老年人
  • 孩子们

14. 按地区分類的爱滋病临床试验市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：按组别分類的爱滋病临床试验市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：各国爱滋病临床试验市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Gilead Sciences, Inc.
    • ViiV Healthcare Limited
    • Merck & Co., Inc.
    • Johnson & Johnson
    • Roche Holding AG
    • Pfizer Inc.
    • AbbVie Inc.
    • Sanofi SA
    • Moderna, Inc.
    • Takeda Pharmaceutical Company Limited
Product Code: MRR-7C50F273957B

The HIV Clinical Trials Market is projected to grow by USD 2.19 billion at a CAGR of 7.43% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.23 billion
Estimated Year [2025] USD 1.33 billion
Forecast Year [2032] USD 2.19 billion
CAGR (%) 7.43%

A concise framing of the contemporary HIV clinical trials landscape highlighting innovation drivers, operational constraints, and strategic imperatives for stakeholders

The global effort to develop safe, effective, and accessible HIV therapies has entered a period of intensified innovation and practical recalibration. Scientific advances in antiviral mechanisms, improvements in trial design, and an increasing emphasis on patient-centered outcomes have combined with heightened expectations for operational efficiency and equitable access. Simultaneously, sponsors, investigators, and trial sites face evolving regulatory expectations and supply-chain complexities that require adaptive planning.

This executive summary provides decision-makers with a focused synthesis of the forces shaping contemporary HIV clinical trials. It identifies core scientific and operational drivers, highlights systemic risks that can impede development timelines, and surfaces practical levers stakeholders can use to strengthen program resilience. By integrating clinical, logistical, and policy perspectives, the summary gives leaders a clear vantage point from which to prioritize investments, refine partnerships, and accelerate translational pipelines while maintaining ethical and regulatory rigor.

Throughout, the analysis emphasizes actionable clarity: where to allocate resources to improve recruitment and retention, how to anticipate and manage cross-border operational friction, and which collaborative models have demonstrated the greatest potential to shorten time to reliable evidence without compromising safety or data integrity.

How scientific breakthroughs, regulatory modernization, and digital transformation are collectively redefining HIV clinical trial paradigms and operational priorities

HIV clinical trials are being reshaped by a conjunction of scientific breakthroughs, digital transformation, and policy evolution. Advances in molecular virology and novel drug modalities have expanded the therapeutic toolkit, while adaptive trial designs and decentralized elements have begun to change how participants are recruited, monitored, and retained. These shifts reduce conventional bottlenecks and create opportunities to test more targeted hypotheses with greater efficiency. At the same time, the adoption of digital endpoints, remote monitoring platforms, and electronic source data capture is enabling more continuous, patient-centric assessments and reducing site burden.

Regulatory agencies worldwide are also signaling increased openness to innovative approaches, particularly when studies are designed with clear risk mitigation and robust data quality controls. This regulatory receptivity, however, comes with heightened expectations around data provenance, device validation, and participant protections, which require early dialog and alignment. Moreover, the emergence of public-private partnerships and academic-industry consortia is accelerating translational research while raising important questions about data sharing, IP stewardship, and equitable distribution of benefits.

As these transformative forces coalesce, stakeholders must balance speed with rigor, and innovation with access. Pragmatic integration of new technologies, coupled with deliberate stakeholder engagement and strengthened supply resilience, will determine which programs realize their potential to deliver meaningful clinical advances.

Assessing how United States tariff measures and related trade policy shifts are reshaping HIV clinical trial supply chains, operational costs, and international collaboration dynamics

Recent tariff measures implemented by the United States and related trade policy shifts have had a pronounced indirect effect on the HIV clinical trials ecosystem, primarily by altering upstream cost and logistics dynamics without directly changing scientific paradigms. Tariffs on active pharmaceutical ingredients, specialized laboratory equipment, and essential packaging components can increase procurement lead times and elevate routine sourcing costs for investigational product manufacturing and clinical supply chains. In turn, sponsors and contract manufacturers have increasingly prioritized dual sourcing, inventory buffering, and closer coordination with customs brokers to preserve study timelines.

Beyond material costs, tariffs can complicate cross-border collaborations that underpin global trial networks. Research sites that rely on imported diagnostic reagents or cold-chain logistics may experience episodic shortages or face unexpected customs delays, which can disrupt specimen handling and compromise data integrity if not proactively managed. Additionally, tariff-driven cost pressure can intensify negotiations around pricing for ancillary services, leading some sponsors to re-evaluate the geographic distribution of laboratory services, central lab consolidation, or greater reliance on regional suppliers.

Importantly, tariff effects intersect with policy and operational responses: regulatory flexibility for alternative supplier validation, accelerated import permits for clinical supplies, and contractual clauses that allocate risk among sponsors and providers. Looking ahead, industry leaders should anticipate that tariff volatility will remain a factor in supply planning and should incorporate scenario-based risk assessments, strengthened supplier governance, and enhanced visibility into end-to-end logistics to shield clinical programs from avoidable disruption.

Segmentation-driven perspectives on how therapeutic class, trial phase, care setting, administration route, distribution channel, and patient age intersect to shape strategic trial choices

Segmentation analysis reveals differentiated strategic implications across therapeutic categories, trial stages, care settings, administration routes, distribution channels, and patient demographics. When classified by drug class, therapeutic development priorities vary: Entry Inhibitors such as enfuvirtide and maraviroc focus on targeting initial viral entry mechanisms and often require parenteral administration strategies, whereas Integrase Strand Transfer Inhibitors including bictegravir, dolutegravir, elvitegravir, and raltegravir frequently underpin regimen simplification efforts and demand attention to drug-drug interactions and resistance surveillance. Non-Nucleoside Reverse Transcriptase Inhibitors like efavirenz, etravirine, nevirapine, and rilpivirine bring their own safety and CNS tolerability profiles to trial design, while Nucleoside Reverse Transcriptase Inhibitors-emtricitabine, lamivudine, tenofovir, and zidovudine-remain central to backbone strategies. Protease Inhibitors such as atazanavir, darunavir, fosamprenavir, and lopinavir require evaluation of metabolic and adherence considerations that influence endpoint selection.

By trial phase, the emphasis shifts from safety and proof-of-concept in Phase I and Phase IIa/IIb to broader efficacy and comparative endpoints in Phase III and real-world safety in Phase IV. Trial phase influences sample size, operational complexity, and monitoring intensity, which in turn affects site selection and patient engagement strategies. End-user segmentation underscores different operational models: clinics and hospitals deliver point-of-care recruitment and integrated monitoring, while research institutes, including academic centers and contract research organizations, often provide specialized expertise and centralized data oversight.

Route of administration considerations-injectable, oral, and transdermal-drive both patient acceptability and supply-chain requirements, with injectables requiring cold-chain or sterile compounding competencies and oral regimens emphasizing adherence support. Distribution channel nuances across hospital pharmacies, online pharmacies, and retail pharmacies, with retail further divided into chain and independent outlets, affect dispensing workflows and post-trial access planning. Finally, patient age groups-adult, geriatric, and pediatric-necessitate tailored safety monitoring, consent processes, and endpoint selection to ensure that trials generate clinically actionable evidence for each population segment.

Regional operational and regulatory insights across the Americas, Europe Middle East & Africa, and Asia-Pacific that inform optimized trial site selection and execution strategies

Regional dynamics exert a strong influence on trial design, operational execution, and regulatory engagement. In the Americas, established research infrastructures and mature regulatory frameworks facilitate rapid study start-up for many sponsors, yet geographic diversity within the region necessitates careful site feasibility assessments to ensure representative enrollment and equitable access. Clinical sites in North America often lead in early-phase innovation, while sites across Latin America play a critical role in demonstrating real-world effectiveness and expanding participant diversity.

Europe, Middle East & Africa presents a heterogeneous regulatory landscape where harmonization initiatives coexist with localized requirements. Sponsors operating across this expanse must balance the advantages of experienced academic centers and large patient pools against variable ethics review timelines and administrative processes. In many jurisdictions, investment in capacity building, standardized data-capture practices, and early regulatory dialogue proves essential to mitigate delays and maintain data quality.

Asia-Pacific combines rapidly growing clinical research capacity with variable reimbursement and regulatory pathways. The region offers opportunities for accelerated enrollment and access to diverse patient populations, but success depends on culturally adapted recruitment strategies, local investigator engagement, and robust supply-chain planning to navigate importation and site provisioning. Across all regions, aligning trial architecture with local clinical practice, engaging community stakeholders, and investing in site training and quality oversight are pivotal to generating high-integrity, generalizable evidence.

Intelligence on influential sponsors, collaborative models, and service providers that are shaping operational excellence and translational momentum in HIV clinical development

The competitive landscape of organizations involved in HIV clinical development reflects a mix of established pharmaceutical sponsors, specialist biologics developers, contract research organizations, academic consortia, and service providers focused on data, logistics, and patient engagement. Established companies continue to leverage deep clinical experience and global development networks to advance large-scale registrational programs, while emerging players and biotech innovators concentrate on differentiated mechanisms of action and targeted populations to carve niche value propositions.

Collaborative models-ranging from strategic alliances between industry and academic centers to multi-stakeholder consortia that share protocols and pooled data-have become more prominent as a way to spread risk and accelerate evidence generation. Contract research organizations and specialty service providers play a critical role in operationalizing complex trial elements such as long-acting injectable manufacturing, cold-chain management, and decentralized trial components. Technology vendors that provide validated electronic data capture, remote monitoring, and interoperable laboratory information systems are increasingly integral to ensuring data integrity and regulatory compliance.

Leadership in this ecosystem depends on integrating scientific clarity with operational excellence. Organizations that combine precise mechanistic hypotheses with robust site governance, flexible supply arrangements, and community-informed recruitment strategies will be best positioned to execute high-quality trials that deliver clinically meaningful outcomes.

Actionable recommendations for sponsors and operational leaders to enhance supply resilience, regulatory alignment, participant engagement, and collaborative research models in HIV trials

Industry leaders should prioritize a set of pragmatic, actionable measures to increase resilience, accelerate evidence generation, and ensure equitable access. First, invest in diversified supplier networks and contractual mechanisms that preserve continuity of investigational product supply and critical laboratory reagents. Second, embed decentralized trial elements judiciously to reduce participant burden while maintaining rigorous monitoring controls and validated remote data capture.

Third, engage regulators and ethics committees early and often to align on adaptive designs, biomarker endpoints, and safety monitoring frameworks; proactive engagement reduces cycles and increases the likelihood of regulatory acceptance. Fourth, design recruitment and retention strategies that are community-informed and culturally sensitive, particularly when trials span multiple regions and demographic groups. Fifth, implement data governance practices that ensure interoperability, traceability, and rapid auditability to meet both regulatory expectations and publication standards.

Finally, cultivate collaborative consortia and public-private partnerships that share noncompetitive data and infrastructure, thereby lowering barriers to entry for smaller developers and accelerating comparative effectiveness research. By integrating these actions into program planning, leaders can reduce operational risk, optimize resource allocation, and increase the probability that trials generate clinically consequential and generalizable results.

A transparent, triangulated research methodology that integrates primary interviews, literature review, operational case studies, and rigorous validation to ensure reliable trial intelligence

The analysis underpinning this report draws on a triangulated research approach that combines primary interviews with key opinion leaders, secondary review of peer-reviewed literature and public regulatory documents, and operational case studies of recent HIV trial programs. Primary inputs include structured interviews with clinical investigators, trial operations leaders, supply-chain managers, and patient-advisory representatives to capture frontline challenges and emergent best practices. Secondary sources encompass clinical study reports, regulatory guidance documents, and methodological literature that inform trial design, safety monitoring, and endpoint selection.

Analytical frameworks employed include risk mapping for supply-chain vulnerability, decision-tree modeling for site selection, and stakeholder impact matrices to prioritize mitigation strategies. Validation steps incorporated cross-checks between interview insights and documented trial outcomes, as well as iterative reviews with external subject matter experts to ensure interpretive accuracy. Quality controls comprised source verification for all cited regulatory positions and internal audit trails for interview transcripts and synthesis notes.

Limitations are acknowledged, including the dynamic nature of trade policy and regulatory guidance, which may evolve after the report's compilation. To mitigate these constraints, the methodology emphasizes transparent assumptions, scenario-based analyses, and clear delineation between observed practice and expert projection, thereby enabling readers to adapt the findings to their specific operational contexts.

A strategic synthesis that integrates operational imperatives, collaborative approaches, and participant-centered design to guide effective HIV clinical development decisions

Bringing together scientific, operational, and policy perspectives yields a coherent set of priorities for organizations engaged in HIV clinical development. The most immediate imperative is to harmonize innovative trial design with pragmatic execution: leverage adaptive and decentralized elements to increase efficiency while ensuring validated data flows and regulatory acceptability. Equally important is treating supply-chain resilience and supplier governance as integral components of trial feasibility rather than as afterthoughts, given their demonstrated capacity to delay enrollment and compromise specimen handling.

Strategically, sponsors should pursue collaborative architectures that combine the strengths of industry, academia, and specialized service providers to accelerate translational pathways and broaden access to diverse participant cohorts. Operational leaders must invest in digital and human infrastructure that supports remote monitoring, standardized laboratory practices, and culturally tailored recruitment. Finally, sustained engagement with regulators and community stakeholders will smooth the path for novel endpoints and increase public trust in trial results.

Taken together, these imperatives set a practical agenda: integrate scientific ambition with operational rigor, anticipate and mitigate supply and policy risks, and center participant needs in study design. Organizations that execute along these lines will be better positioned to deliver robust, actionable evidence that advances therapy and access for people living with HIV.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of long-acting injectable antiretroviral therapies into routine HIV management to improve adherence
  • 5.2. Advancements in broadly neutralizing antibody trials targeting diverse HIV-1 clades for broader efficacy
  • 5.3. Implementation of decentralized clinical trial models leveraging telemedicine for enhanced patient retention in HIV studies
  • 5.4. Development of dual-acting therapeutic vaccines aiming to both boost immunity and reduce reservoir size in HIV patients
  • 5.5. Exploration of CRISPR-based gene editing approaches for potential functional cure in early-phase HIV clinical trials
  • 5.6. Adoption of real-world data analytics to inform adaptive trial designs and optimize HIV drug development pipelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. HIV Clinical Trials Market, by Drug Class

  • 8.1. Entry Inhibitors
    • 8.1.1. Enfuvirtide
    • 8.1.2. Maraviroc
  • 8.2. Integrase Strand Transfer Inhibitors
    • 8.2.1. Bictegravir
    • 8.2.2. Dolutegravir
    • 8.2.3. Elvitegravir
    • 8.2.4. Raltegravir
  • 8.3. Non-Nucleoside Reverse Transcriptase Inhibitors
    • 8.3.1. Efavirenz
    • 8.3.2. Etravirine
    • 8.3.3. Nevirapine
    • 8.3.4. Rilpivirine
  • 8.4. Nucleoside Reverse Transcriptase Inhibitors
    • 8.4.1. Emtricitabine
    • 8.4.2. Lamivudine
    • 8.4.3. Tenofovir
    • 8.4.4. Zidovudine
  • 8.5. Protease Inhibitors
    • 8.5.1. Atazanavir
    • 8.5.2. Darunavir
    • 8.5.3. Fosamprenavir
    • 8.5.4. Lopinavir

9. HIV Clinical Trials Market, by Trial Phase

  • 9.1. Phase I
  • 9.2. Phase II
    • 9.2.1. Phase IIa
    • 9.2.2. Phase IIb
  • 9.3. Phase III
  • 9.4. Phase IV

10. HIV Clinical Trials Market, by End User

  • 10.1. Clinics
  • 10.2. Hospitals
  • 10.3. Research Institutes
    • 10.3.1. Academic Institutes
    • 10.3.2. Contract Research Organizations

11. HIV Clinical Trials Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Oral
  • 11.3. Transdermal

12. HIV Clinical Trials Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies
    • 12.3.1. Chain Pharmacies
    • 12.3.2. Independent Pharmacies

13. HIV Clinical Trials Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Geriatric
  • 13.3. Pediatric

14. HIV Clinical Trials Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. HIV Clinical Trials Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. HIV Clinical Trials Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Gilead Sciences, Inc.
    • 17.3.2. ViiV Healthcare Limited
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. Johnson & Johnson
    • 17.3.5. Roche Holding AG
    • 17.3.6. Pfizer Inc.
    • 17.3.7. AbbVie Inc.
    • 17.3.8. Sanofi S.A.
    • 17.3.9. Moderna, Inc.
    • 17.3.10. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HIV CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-203